Guizhou Xinbang Pharmaceutical Co., Ltd.
002390.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.85B
Close$
$7.24
154.1% upside
Current Fair Value
154.1% upsideUndervalued by 154.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.85 Billion |
|---|---|
| Enterprise Value | $4.87 Billion |
| Dividend Yield | $0.09 (2.99%) |
| Earnings per Share | $0.06 |
| Beta | 0.21 |
| Outstanding Shares | 1,896,406,328 |
Return
| Return on Equity | 1.67% |
|---|---|
| Return on Assets | 1.34% |
| Return on Invested Capital | 3.26% |
Valuation & Multiples
| P/E Ratio | 50.67 |
|---|---|
| PEG | -222.46 |
| Price to Sales | 1.43 |
| Price to Book Ratio | 0.95 |
| Enterprise Value to Revenue | 0.93 |
| Enterprise Value to EBIT | 21.12 |
| Enterprise Value to Net Income | 43 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$2.24 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$2.24 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Guizhou Xinbang Pharmaceutical Co., Ltd.
4,702 employees
CEO: Lingzhong Kong Guizhou Xinbang Pharmaceutical Co., Ltd. specializes in the entire process of researching, developing, manufacturing, and distributing both traditional Chinese herbal medicines and cutting-edge biological pharmaceuticals. The company's o...